Suzhou Labyrinth Biotech Co., Ltd., based in Suzhou Industrial Park, focuses on the cutting-edge field of global precision medicine. The company has built a technology platform centered on AI-powered liquid biopsy, leveraging its independently developed next-generation Labyrinth microfluidic chip system and rare cell capture technology to advance precision cancer therapy.
Our team consists of 26 members and expert advisors—most of whom have backgrounds with Fortune 500 pharmaceutical companies or prestigious institutions such as Yale University, MIT, and Peking University, possessing deep expertise in precision medicine, microfluidics, liquid biopsy, and data analysis.
We hold more than 40 patents (over 20 granted) and operate in compliance with NMPA, FDA, CE, and ISO 13485 standards, providing scalable, non-invasive solutions to enable personalized, real-time cancer treatment worldwide.
- 01Carry out scientific research cooperation projects with the National University of Singapore
- 01Establish a results transformation project with the Second Affiliated Hospital of Nanchang University
- 02Carry out collaborative research and development projects with the Affiliated Tumor Hospital of Sun Yat-sen University
- 03Carry out scientific research cooperation projects with Fudan University Affiliated Cancer Hospital
- 04Carry out scientific research cooperation projects with the First Affiliated Hospital of Soochow University
- 05CE01 PRO Machine Development Upgrade
- 06Awarded the '2024 Future Healthcare Top 100 Selection · Innovative Products in the Medical and Health Industry List'
- 01ISO 13485 Quality Management System Certification · CE (EU) Certification
- 02Awarded the 'High-Tech Enterprise' certification
- 03Signed a POCT direction development order worth millions with Molarray
- 04Carry out in-depth cooperation with Peking Union Medical College Hospital in precision medicine translation
- 01The first automated prototype machine has been developed
- 02Obtain NMPA (China) & FDA (USA) certification
- 03Carry out clinical trial projects with the First Affiliated Hospital of University of Science and Technology of China
- 01Awarded the title of 'Gusu Leading Talent in Innovation and Entrepreneurship'
- 02Begin providing clinical and research services
- 03Achieve overseas sales of chips
Transform cancer diagnosis through AI-driven CTC liquid biopsy technology -----Providing accurate, real-time, and non-invasive solutions for early detection and treatment monitoring in China and globally.
Lead the global shift towards precision medicine, making CTC-based liquid biopsy the new clinical standard -----Connecting cutting-edge science with scalable impact on healthcare systems worldwide.
-
Chen TaoFounder and Chairman• Many years of experience in operating listed companies and possessing extensive industry resources across the financial sector
• Long-term dedication to cross-border equity investment, project financing, mergers and acquisitions, and government relations in the biopharmaceutical and biotechnology industries -
Majid E. Warkani, PhDChief Technology Officer• Professor of Biomedical Engineering at the University of Technology Sydney
• Internationally distinguished expert in liquid biopsy, leader of multiple independent international projects
• Recipient of the Young Tall Poppy Science Award (2019), MIT Technology Review Innovators Under 35 (2016), and Nanyang Young Alumni Award (2017)
• Published over 200 papers in high-level international journals including Nature Protocols and Nature Communications -
Yang Naibo, Ph.D.Chief Executive Officer and Chief Scientific Officer• Ph.D. in Physiology/Neurobiology from Thomas Jefferson University; Postdoctoral Fellow in Molecular and Cellular Physiology at Stanford University; 20 years of management experience in the biopharmaceutical/diagnostics industry in China and the United States
• Co-founder and COO of a subsidiary of BGI; former CEO/R&D head/board member of innovative drug companies, leading key cross-departmental decisions
• Familiar with FDA and NMPA regulatory pathways, promoted multiple rounds of financing during industry adjustment periods, skilled in translating technology into company-level strategy and growth paths
• Published 300 papers in tumor immunology, antibody engineering, cell therapy, and precision medicine; holds multiple core patents
-
Yu Hanry, PhDChief Scientific Advisor• Postdoctoral fellow at Heidelberg Bioscience Laboratory, PhD from Duke University
• Tenured professor at Yong Loo Lin School of Medicine, National University of Singapore, Chief Scientist of the Cell and Tissue Engineering Laboratory, and concurrently Co-Chief Scientist of the Critical Analysis Project (CAMP) for Personalized Medicine Manufacturing under the Singapore-MIT Alliance for Research and Technology (SMART)
• Focuses on biomaterials, tissue engineering, biomedical imaging, and lab-on-a-chip fields, committed to translating various expertise into applications such as cell- or organoid-based in vitro models, drug or toxin testing methods, and more
Contact Us
We will respond to your questions as soon as possible.
If you do not receive an answer within 3 working days, please call the service hotline at 0512-66033228.